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Abstract  
BACKGROUND: Human immunodeficiency virus (HIV) infection is an epidemic worldwide, despite the marked 
benefits of antiretroviral therapy (ARV) in reducing severe HIV-associated dementia. A milder form of 
neurocognitive disorders are still prevalent and remain a challenge.  
AIM: This study aimed to determine the correlation between plasma cluster of differentiation 4 (CD4) lymphocyte, 
duration of ARV treatment, opportunistic infections, and cognitive function in HIV-AIDS patients.  
METHODS: A cross-sectional study involving 85 HIV-AIDS patients was conducted at Adam Malik General 
Hospital Medan, Indonesia. All subjects were subjected to physical, neurologic examination and Montreal 
Cognitive Assessment-Indonesian Version (MoCA-INA) to assess cognitive function and measurement of 
lymphocyte CD4 counts.  
RESULTS: Out of the 85 subjects evaluated, the proportion concerning sexes include 52 males (61.2 %) and 33 
females (38.8%). The mean age was 38.53 ± 9.77 years old. There was a significant correlation between CD4 
lymphocyte counts and MoCA-INA score (r = 0.271, p = 0.012), but there was no significant correlation between 
duration of ARV treatment and MoCA-INA score. There was also no difference in MoCA-INA score based on the 
presence of opportunistic infection.  
CONCLUSION: Lymphocyte CD4 count was independently correlated with cognitive function in HIV-AIDS 
patients. 
 
 
Introduction 
 
Human immunodeficiency virus (HIV) 
infection is a global epidemic. According to estimates 
from the 2017 UNAIDS report on the global Acquired 
Immunodeficiency Syndrome (AIDS) epidemic, there 
were approximately 36.7 million people living with HIV 
worldwide [1]. There were 15,534 people with HIV 
infection and 1700 AIDS cases at the end of 2014 in 
Indonesia, with a cumulative number from April 1987 
to 2014 stands at 142,950 HIV cases and 55,623 
AIDS cases. The cumulative number of HIV-AIDS 
cases in Sumatera Utara province ranked tenth in 
Indonesia, with 8,794 HIV cases and 1,573 AIDS 
cases at the end of 2014, with a prevalence of 12.12 
per 100.000 population [2]. 
Neurologic disorders in HIV infection can be 
divided into primary and secondary disorders. The 
secondary disorders are caused by opportunistic 
infections resulting from immunosuppression and 
have become less frequently found since the 
establishment of antiretroviral (ARV) treatment. The 
primary disorders, including HIV-associated 
neurocognitive disorders (HAND) representing the 
deleterious effects of HIV on brain [3] [4] [5] There are 
three severity categories for HAND: HIV-associated 
asymptomatic neurocognitive impairment (ANI), HIV -
associated mild neurocognitive disorder (MND), and 
HIV-associated dementia (HAD). Although the use of 
ARV has made severe forms of cognitive impairment 
less common, mild to moderate degrees of cognitive 
disturbances have become more prevalent and 
remain a challenge [6] [7] [8]. ARV has improved 
survival substantially and may also reverse 
neurocognitive deficits in many cases. The impact of 
recognising ANI in clinical practice and research 
would be to encourage more frequent 
neuropsychologic assessment for individuals with ANI, 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
2                                                                                                                                                                                                    https://www.id-press.eu/mjms/index 
 
to detect early cognitive changes, functional 
impairments and potential transition to MND or HAD. 
It might also promote the initiation of ARV 
independent of CD4 count or plasma HIV RNA levels, 
especially in the developing countries where 
measurement of plasma viral load are not readily 
available, or in a limited resource setting [8].  
This study aimed to determine the correlation 
between plasma CD4 lymphocyte count, ARV 
duration, opportunistic infection and cognitive function 
in HIV-AIDS patients. 
 
 
Methods 
 
This was a cross-sectional study conducted in 
Adam Malik General Hospital Medan North Sumatera 
Indonesia, between June and November 2017. HIV -
AIDS patients 18 yrs and above were included in this 
study, with the following profiles: compos mentis, 
speak Bahasa Indonesia fluently, ability to read and 
write, and gave written consent. We excluded patients 
who had psychiatric disorders, aphasia, dementia, 
traumatic brain injury and central nervous system 
opportunistic infection. The evaluation encompassed 
standard physical and neurologic examination, 
Montreal Cognitive Assessment-Indonesian Version 
(MoCA-INA) and CD4 lymphocyte measurement.  
All statistical procedures were performed with 
SPSS version 20. We used Pearson’s or Spearman 
correlation test to evaluate the correlation between 
CD4 count, age and cognitive function (MoCA-INA 
score), ANOVA or Kruskal Wallis to evaluate the 
difference on MoCA INA score based on level of 
education and t-test or Mann Whitney to evaluate the 
differences of CD4 count and ARV duration based on 
MoCA-INA score.  
The study was performed with approval 
obtained from the Health Research Ethical Committee 
Medical Faculty of Universitas Sumatera Utara/H. 
Adam Malik General Hospital with number 
325/TGL/KEPK FK USU-RSUP HAM/2017.  
 
 
Results 
Out of the 85 subjects evaluated, the 
proportion concerning sexes includes 52 males (61.2 
%) and 33 females (38.8%). The mean age was 38.53 
± 9.77 years old, ranging from 19 to 65 years old. The 
mean MoCA INA score was 22.94 ± 3.38, ranging 
from 15 to 28. The mean CD4 counts were 432.58 ± 
332.24 cells/L. Table 1 shows characteristics of 
subjects.  
Table 1: Characteristics of Subjects  
Characteristic Number (n = 85) Percentage 
Age (years), mean ± SD 38.53 ± 9.77  
Sex 
Male 
Female 
 
52 
33 
 
61.2 
38.8 
Level of education 
Elementary 
Junior High School 
High School 
College/University 
 
7 
43 
25 
10 
 
8.2 
50.6 
29.4 
11.8 
Occupation 
Entrepreneur 
Employee 
Housewife 
Farmer 
Student 
Unemployed 
 
37 
5 
23 
9 
4 
7 
 
43.5 
5.9 
27.1 
10.6 
4.7 
8.2 
Ethnic 
Batak 
Melayu 
Javanese 
Tionghoa 
Karo 
 
38 
6 
18 
6 
17 
 
44.7 
7.1 
21.2 
7.1 
20.0 
MoCA-INA Score 
≥ 26 
< 26 
 
21 
64 
 
24.7 
75.3 
Opportunistic Infection 
Yes 
No 
 
60 
25 
 
70.6 
29.4 
ARV duration (months), mean±SD, 37.5 ± 25.91  
MoCA-INA Score, mean± SD 22.94 ± 3.38  
Absolute CD4 count (cell/L), mean ± SD 432.58 ± 332.24  
CD4 percentage (%), mean±SD 18.80 ± 9.93  
 
There was no significant difference on MoCA-
INA score based on the level of education (Table 2). 
There was also no significant correlation between age 
and MoCA-INA score (r = 0.034, p = 0.76).  
Table 2: Comparison of MoCA-INA Scores based on the level of 
education 
Level of education Mean ± SD p 
Elementary school 23.14 ± 3.80 0.849* 
Junior high school 22.74 ± 3.37  
High school 23.40 ± 3.58  
College 22.50 ± 2.95  
SD = standar deviation; *Kruskal-Wallis Test. 
 
 
The absolute lymphocyte CD4 count and 
lymphocyte CD4 percentage were significantly 
different based on MoCA INA score, but there was no 
significant difference in ARV duration based on 
MoCA-INA score. 
Table 3: Differences in the CD4 absolute count, CD 4 
percentage and ARV duration based on MoCA-INA Score 
MoCA-INA Score Lymphocyte CD4 absolute 
count (cell/L) 
Lymphocyte CD4 
percentage (%) 
ARV Duration (months) 
Mean ± SD p Mean ± SD p Mean ± SD p 
Normal (n = 21) 591.35 ± 369.33 0.003 22.94 ± 9.35 0.010 45.12 ± 38.54 0.914 
Abnormal (n = 64) 283.00 ± 258.18 14.83 ± 9.29 38.39 ± 24.3 
Mann Whitney. 
 
There was a significant correlation between 
absolute CD4 lymphocyte count and MoCA-INA score 
(r = 0.271, p = 0.015) and between percentage CD4 
count and MoCA-INA Score (r = 0.227, p = 0.037). 
Figure 1 shows the MoCA-INA Score plotted against 
absolute CD4 lymphocyte counts. The normal MoCA 
INA score should be above or equal to 26. In this 
study, most of the subjects had scored lower than 26 
(n = 64), and from that 64 subjects, most of them had 
scored between 21-25, but the overall mean score 
was 22.94 ± 3.38.  
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Figure 1: MoCA-INA Score plotted against CD4 lymphocyte counts 
 
The duration of ARV treatment was 37.5 ± 
25.91 months. There was no significant correlation 
between duration of ARV treatment with MoCA-INA 
score (r = 0.091, p = 0.407). Most of the subjects (60 
patients, 70.6%) had an opportunistic infection which 
was lung tuberculosis. There was no significant 
difference on MoCA-INA score based on the presence 
of opportunistic infection (Table 4). 
Table 4: Comparison of MoCA-INA Scores based on the 
presence of opportunistic infection 
Opportunistic Infection Mean ± SD p 
Yes 23.02 ± 3.29 0.625 
No 22.76 ± 3.64  
Mann Whitney Test. 
 
 
 
Discussion 
 
Our data show that there was a significant 
correlation between CD4 lymphocyte count with 
cognitive function in HIV-AIDS patients as measured 
by MoCA-INA score. This correlation was independent 
of age and level of education. This is in line with 
several previous studies [9] [10] [11] [12]. Valcour et 
al. (2006) [9] found that after adjusting for age and 
duration of HIV, lowest historical CD4 was related to a 
current diagnosis of HAD (odds ratio 1.395 (1.106-
1.761) Patients with CD4 lymphocyte below 200 
cells/mm
3
 were considered highly vulnerable to 
neurological complications associated with infection, 
including cognitive impairment and the risk increased 
with further reductions in CD4 lymphocyte count [9]. 
Ellis et al. (2011) [10] found that lowest historical CD4 
was a predictor of HIV neurocognitive impairment in 
the era of a combination of antiretroviral therapy [10]. 
A study by Childs et al. (1999) [11] found that levels of 
plasma CD4 counts and HIV RNA were predictive of 
HAD and it develops in parallel with immunodeficiency 
and with more advanced stages of HIV [11]. This 
finding could partially reflect the effect of marked 
immunodeficiency in HIV patients to cognitive 
function. The correlation between CD4 count and 
cognitive function was also independent of the 
duration of ARV treatment and the presence of 
opportunistic infection. A study by Reger et al. (2005) 
[12]. Suggested that plasma HIV RNA levels may not 
predict the degree of neurobehavioral disturbances in 
HIV infection among patients receiving ARV treatment 
[12]. HIV causes damage in the central nervous 
system through two separate but linked processes: 
the first is a host-derived cascade of inflammatory 
molecules released by activated or infected microglia, 
macrophages and astrocytes and the second process 
involves the direct neurotoxic effects of HIV-encoded 
proteins such as gp120, Vpr, and Tat, which also 
modulate transcription of HIV-1 long terminal repeat 
(LTR) promoter activity and affects several cellular 
functions [5]. The neuronal damage that occurs is 
likely caused by shedding viral proteins such as 
gp120 and Tat or indirectly through the elevated 
production of neurotoxic molecules released by 
activated astrocytes macrophages and microglia [6]. 
Although neurons are not directly infected by HIV, 
secondary neuronal damage caused by other infected 
cells is probably required to cause cognitive 
impairment [4]. HIV infection causes damage to the 
elaborate network of connections between neurons 
that take place at dendrites and synapses. This 
synaptodendritic injury disrupts the highly integrated 
functioning of neural systems that are required to 
process information, leading to HIV -associated 
neurocognitive disorders (HAND), which consist of 
asymptomatic neurocognitive impairment (ANI), HIV-
associated mild neurocognitive disorder (MND), and 
HIV-associated dementia (HAD) [8]. ANI describes 
individuals with usually mild impairment in two or more 
cognitive areas, demonstrated by neuropsychological 
testing, without a clear effect on everyday functioning. 
MND refers to the presence of mild to moderate 
deficits in two or more cognitive areas which create at 
least mild interference in everyday functioning. Finally, 
HAD describes individuals with documented moderate 
to severe deficits in two or more cognitive areas, with 
substantial impairment in everyday functioning making 
the person incapable of employment and often unable 
to live independently [6] [8]. 
Our study did not classify the cognitive 
impairment further based on the cognitive domains. 
MoCA-INA was only used to assess cognitive 
function. It can assess several domains, including 
executive function, visuospatial function, attention and 
concentration, memory, language, calculation and 
orientation [13]. The Indonesian version of MoCA, 
namely MoCA-INA has been developed and validated 
in Indonesia, and so it can be used as a cognitive tool 
[14]. HIV infection characteristically generates a “sub-
cortical” pattern of neurocognitive dysfunction with 
deficits predominantly affecting executive functions, 
speed of information processing, attention/working 
memory, motor speed, new learning and retrieval of 
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new information, while long-term (semantic) memory, 
many language skills, and visuo -spatial abilities may 
remain intact [6]. The pattern of neurocognitive 
dysfunction, however, is not consistent across 
individuals and may be even less consistent across 
individuals from markedly different backgrounds [5]. 
MND is often an antecedent syndrome that can 
precede the onset of frank dementia but presents with 
the clinical hallmarks of HAD albeit with less-severe 
signs and symptoms and at higher CD4þ T-cell levels. 
Symptoms of HAD typically begin once an individual’s 
lymphocyte CD4 count drops below 200 cells/mL. 
Clinical risk factors for HAD include low CD4 T-cell 
levels, high viral load in cerebrospinal fluid (CSF) or 
plasma, anaemia, extremes of age, injection drug use, 
and several host genetic polymorphisms [6]. This 
study did not analyse the factors that could associate 
with CD4 counts. A study by Li et al (20110 [15] found 
several important modifiable risk factors were 
associated with lower CD4 counts, including older age 
(> 50 years), lower CD4 counts at the time of HAART 
initiation, the number of switches in HAART regimen 
in the first 5 years and hepatitis B and C virus 
infection [15]. 
An interesting finding from this study was the 
fact that the number of patients with abnormal 
cognitive function (MoCA-INA score < 26) was higher 
than the number of patients with normal cognitive 
function (MoCA-INA score ≥ 26), although most of the 
patients did not have any subjective cognitive 
complaint. Although this finding could be attributed to 
the fact that most of the patients had a level of 
education lower than 12 years, there were no 
significant differences in MoCA-INA score based on 
the level of education, also there was no significant 
correlation between age and cognitive function. This 
could emphasise the importance of cognitive 
assessment in HIV-AIDS patients to evaluate HIV 
effects on the CNS, to detect early cognitive changes, 
functional impairments and potential transition to MND 
or HAD.  
This study concludes that CD4 lymphocyte 
count correlates with cognitive function in HIV-AIDS 
patients. This finding could reflect that immune status 
as marked partly by CD4 count might contribute to the 
development of CNS complications, including 
cognitive dysfunction.  
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